Skeletal Dysplasias
Mind-Body Issues
Related Conditions/Issues
Clinical Trials
- The Kathryn O. and Alan C. Greenberg Center for Skeletal Dysplasias Clinical Research Registry
- A Randomized Double Blind Placebo Controlled Multi-Center Parallel Group Study of One Year Duration Followed by Two Years of open-label Treatment to Determine the Safety and Efficacy of Orally Administered 2.5 mg or 5.0 mg Daily Risedronate
Enter a last name to search for information about a doctor.
Patient Stories:
In the News:
- Contact HSS
- Give to HSS
- Maps and Directions
- Notice of Privacy Practices
- Terms of Use
- Joint Commission Notice
- HSS Staff Login
© Hospital for Special Surgery. 535 East 70th Street, New York, NY 10021
